Phenotypic and transcriptomic profiling of induced pluripotent stem cell (iPSC)-derived NK cells and their cytotoxicity against cancers.

Nontaphat Thongsin, Siriwal Suwanpitak, Punn Augsornworawat, Jakkrapatra Srisantitham, Kritayaporn Saiprayong, Piroon Jenjaroenpun, Methichit Wattanapanitch
Author Information
  1. Nontaphat Thongsin: Siriraj Center for Regenerative Medicine, Research Department, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, 10700, Thailand.
  2. Siriwal Suwanpitak: Siriraj Center for Regenerative Medicine, Research Department, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, 10700, Thailand.
  3. Punn Augsornworawat: Department of Immunology, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand.
  4. Jakkrapatra Srisantitham: Siriraj Center for Regenerative Medicine, Research Department, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, 10700, Thailand.
  5. Kritayaporn Saiprayong: Siriraj Center for Regenerative Medicine, Research Department, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, 10700, Thailand.
  6. Piroon Jenjaroenpun: Division of Medical Bioinformatics, Research Department, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand.
  7. Methichit Wattanapanitch: Siriraj Center for Regenerative Medicine, Research Department, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, 10700, Thailand. methichit.wat@mahidol.ac.th. ORCID

Abstract

BACKGROUND: Adoptive immunotherapy using natural killer (NK) cells has attracted considerable interest in numerous clinical trials targeting both hematological and solid tumors. Traditionally, NK cells are primarily derived from either peripheral blood (PB) or umbilical cord blood (UCB). However, these methods can lead to variability and heterogeneity within the NK cell population. In contrast, induced pluripotent stem cell (iPSC)-derived NK (iNK) cells provide a more controlled and uniform cellular population, suitable for large-scale clinical applications. This makes iNK cells a promising option for developing "off-the-shelf" immunotherapeutic products. Nevertheless, current NK cell differentiation protocols, which rely on embryoid body (EB) cultures, are labor-intensive and susceptible to unwanted heterogeneity during differentiation. Here, we developed a more efficient approach for generating iNK cells by employing a monolayer and feeder-free differentiation protocol, alongside optimized culture media.
METHODS: The iNK cells were generated using a two-step in vitro monolayer feeder-free system following NK cell development. To evaluate their maturity, phenotypic analysis was performed using flow cytometry, comparing with PB-NK cells and the NK-92 cell line. Additionally, single-cell RNA sequencing was performed to examine their transcriptomic profiles. The cytotoxic activity of the iNK cells was evaluated by co-culturing with cholangiocarcinoma (CCA) and breast cancer (BCA) cell lines in both monolayer (2D) and tumor spheroid (3D) co-culture systems.
RESULTS: We successfully differentiated iPSCs into mesoderm (ME), hematopoietic stem/progenitor cells (HSPCs), and NK cells. The resulting iNK cells exhibited typical NK cell markers such as CD45, CD56, and CD16, and expressed key functional proteins, including both activating and inhibitory receptors. Single-cell RNA sequencing confirmed that the transcriptomic profile of our iNK cells closely resembles that of PB-NK cells. Importantly, our iNK cells demonstrated strong cytotoxic abilities against various CCA and BCA cell lines, surpassing the NK-92 cell line in both monolayer cultures and tumor spheroid cultures.
CONCLUSION: This study highlights the potential of iPSCs as an effective alternative cell source for generating NK cells. Using a two-step in vitro monolayer feeder-free system, we successfully generated iNK cells that not only expressed key NK cell markers and their receptors but also displayed a transcriptomic profile closely resembling PB-NK cells. Furthermore, iNK cells exhibited cytotoxicity against CCA and BCA cell lines comparable to that of PB-NK cells. This approach could pave the way for off-the-shelf NK cell products, potentially enhancing the effectiveness of adoptive NK cell therapy.

References

  1. Nat Commun. 2019 Sep 2;10(1):3931 [PMID: 31477722]
  2. Cancer Immunol Res. 2022 Feb;10(2):215-227 [PMID: 34937729]
  3. World J Stem Cells. 2020 Jan 26;12(1):25-34 [PMID: 32110273]
  4. J Allergy Clin Immunol. 2013 Sep;132(3):536-544 [PMID: 23906377]
  5. Cell Stem Cell. 2021 Dec 2;28(12):2062-2075.e5 [PMID: 34525347]
  6. Nat Rev Cancer. 2022 Oct;22(10):557-575 [PMID: 35879429]
  7. Transfus Med Hemother. 2017 Jun;44(3):143-150 [PMID: 28626365]
  8. Stem Cell Res. 2021 Oct;56:102551 [PMID: 34628247]
  9. Cell Mol Immunol. 2019 May;16(5):430-441 [PMID: 30778167]
  10. Immunity. 2016 May 17;44(5):989-1004 [PMID: 27192565]
  11. Blood. 2005 Apr 15;105(8):3051-7 [PMID: 15632206]
  12. Cell Mol Immunol. 2021 May;18(5):1290-1304 [PMID: 33239726]
  13. Sci Transl Med. 2020 Nov 4;12(568): [PMID: 33148626]
  14. Trends Immunol. 2022 Jul;43(7):503-512 [PMID: 35654639]
  15. Ann Transl Med. 2019 Mar;7(5):105 [PMID: 31019955]
  16. Pediatr Res. 2005 May;57(5 Pt 1):649-55 [PMID: 15718362]
  17. Stem Cell Res Ther. 2020 Jun 16;11(1):234 [PMID: 32546200]
  18. Front Immunol. 2018 Aug 13;9:1869 [PMID: 30150991]
  19. Cell Discov. 2022 Nov 8;8(1):121 [PMID: 36344493]
  20. Blood. 2009 Jun 11;113(24):6094-101 [PMID: 19365083]
  21. Cancers (Basel). 2019 Jun 03;11(6): [PMID: 31163679]
  22. Cytotherapy. 2021 Oct;23(10):939-952 [PMID: 34272175]
  23. Stem Cell Res. 2023 Sep;71:103138 [PMID: 37343428]
  24. Nat Rev Drug Discov. 2020 Mar;19(3):200-218 [PMID: 31907401]
  25. Annu Rev Immunol. 2021 Apr 26;39:417-447 [PMID: 33902312]
  26. Front Oncol. 2018 Jul 20;8:268 [PMID: 30079312]
  27. Blood. 2012 Jan 12;119(2):399-410 [PMID: 22096237]
  28. Blood. 2010 Jan 14;115(2):274-81 [PMID: 19897577]
  29. Front Immunol. 2015 Nov 17;6:578 [PMID: 26635792]
  30. Sci Rep. 2015 Jul 16;5:12113 [PMID: 26178856]
  31. Cell. 2010 Sep 17;142(6):847-56 [PMID: 20850008]
  32. Front Immunol. 2022 Feb 03;13:841107 [PMID: 35185932]
  33. Sci Rep. 2014 Dec 10;4:7402 [PMID: 25492588]
  34. Cancer Biol Med. 2022 Jul 21;19(9): [PMID: 35856557]
  35. Nat Rev Immunol. 2023 Feb;23(2):90-105 [PMID: 35637393]
  36. Blood. 2022 Dec 8;140(23):2451-2462 [PMID: 35917442]
  37. Cell Regen. 2023 Sep 1;12(1):31 [PMID: 37656237]
  38. Stem Cell Reports. 2017 Dec 12;9(6):1796-1812 [PMID: 29173894]
  39. Exp Hematol. 2019 Mar;71:13-23 [PMID: 30611869]
  40. Cells. 2024 Mar 05;13(5): [PMID: 38474415]
  41. Signal Transduct Target Ther. 2023 Apr 12;8(1):160 [PMID: 37045827]
  42. Stem Cell Res. 2018 Mar;27:105-108 [PMID: 29367084]
  43. Cell Stem Cell. 2020 Aug 6;27(2):224-237.e6 [PMID: 32531207]
  44. Methods Mol Biol. 2019;2048:107-119 [PMID: 31396935]
  45. Semin Immunopathol. 2019 Jan;41(1):59-68 [PMID: 30361801]
  46. Nat Immunol. 2008 May;9(5):503-10 [PMID: 18425107]
  47. Front Immunol. 2023 Jul 18;14:1192907 [PMID: 37539051]
  48. Front Immunol. 2022 May 16;13:896228 [PMID: 35651603]
  49. Cell Stem Cell. 2018 Aug 02;23(2):181-192.e5 [PMID: 30082067]
  50. Immunotargets Ther. 2021 Nov 01;10:387-407 [PMID: 34754837]
  51. Blood. 2020 Feb 6;135(6):399-410 [PMID: 31856277]
  52. Stem Cell Res Ther. 2020 Nov 11;11(1):481 [PMID: 33176890]

Grants

  1. R016633005/Faculty of Medicine Siriraj Hospital, Mahidol University
  2. R016637002/Faculty of Medicine Siriraj Hospital, Mahidol University
  3. N41A661130/National Research Council of Thailand
  4. N41A661130/National Research Council of Thailand

MeSH Term

Humans
Killer Cells, Natural
Induced Pluripotent Stem Cells
Cell Differentiation
Transcriptome
Gene Expression Profiling
Phenotype
Neoplasms
Cell Line, Tumor
Immunotherapy, Adoptive

Word Cloud

Created with Highcharts 10.0.0cellscellNKiNKmonolayerPB-NKtranscriptomicusingdifferentiationculturesfeeder-freeCCABCAlinesclinicalbloodheterogeneitypopulationinducedpluripotentstemiPSC-derivedproductsapproachgeneratinggeneratedtwo-stepvitrosystemperformedNK-92lineRNAsequencingcytotoxictumorspheroidsuccessfullyiPSCsexhibitedmarkersexpressedkeyreceptorsprofilecloselycytotoxicityBACKGROUND:AdoptiveimmunotherapynaturalkillerattractedconsiderableinterestnumeroustrialstargetinghematologicalsolidtumorsTraditionallyprimarilyderivedeitherperipheralPBumbilicalcordUCBHowevermethodscanleadvariabilitywithincontrastprovidecontrolleduniformcellularsuitablelarge-scaleapplicationsmakespromisingoptiondeveloping"off-the-shelf"immunotherapeuticNeverthelesscurrentprotocolsrelyembryoidbodyEBlabor-intensivesusceptibleunwanteddevelopedefficientemployingprotocolalongsideoptimizedculturemediaMETHODS:followingdevelopmentevaluatematurityphenotypicanalysisflowcytometrycomparingAdditionallysingle-cellexamineprofilesactivityevaluatedco-culturingcholangiocarcinomabreastcancer2D3Dco-culturesystemsRESULTS:differentiatedmesodermMEhematopoieticstem/progenitorHSPCsresultingtypicalCD45CD56CD16functionalproteinsincludingactivatinginhibitorySingle-cellconfirmedresemblesImportantlydemonstratedstrongabilitiesvarioussurpassingCONCLUSION:studyhighlightspotentialeffectivealternativesourceUsingalsodisplayedresemblingFurthermorecomparablepavewayoff-the-shelfpotentiallyenhancingeffectivenessadoptivetherapyPhenotypicprofilingcancers

Similar Articles

Cited By (1)